PPAR-Modulator and Urolithin Composition for Mitochondrial Rescue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively address mitochondrial dysfunction and energy metabolism issues in cardiac diseases, leading to high morbidity and mortality rates, particularly in conditions like hypertrophic cardiomyopathy and RASopathies, where mitochondrial alterations contribute to disease progression.
Innovation Solution
A pharmaceutical composition combining a PPAR-modulator and an urolithin derivative, such as bezafibrate and urolithin A, is developed to stimulate mitochondrial turnover and energy metabolism, addressing defective organelle bioenergetics, biogenesis, and quality control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for cardiac diseases, then treatment is provided for common cardiac conditions, but mitochondrial dysfunction and energy metabolism issues are not effectively addressed
Solution Approach 1:
The patent combines two previously separate therapeutic approaches into a single composition: PPAR modulators (which regulate lipid metabolism and inflammation) and urolithin derivatives (which stimulate mitochondrial biogenesis and protect against mitochondrial dysfunction). This merging allows the composition to simultaneously address multiple aspects of cardiac disease including conventional cardiovascular protection and mitochondrial dysfunction, thereby resolving the contradiction between general therapeutic effectiveness and specific adaptability to mitochondrial issues.
Solution Approach 2:
The pharmaceutical composition is designed with multi-functionality to address various cardiac conditions through a single intervention. The PPAR modulator component provides broad cardiovascular protection including lipid regulation and anti-inflammatory effects, while the urolithin derivative component specifically targets mitochondrial dysfunction. This universal composition can be applied to multiple cardiac diseases (hypertrophic cardiomyopathy, dilated cardiomyopathy, heart failure) regardless of their primary etiology, thereby achieving both high reliability and broad adaptability.
2Ease of operation
If guideline-directed therapies are used for heart failure, then standard treatment protocols are followed, but morbidity and mortality rates remain unacceptably high
Solution Approach 1:
The invention introduces a new therapeutic parameter (mitochondrial stimulation through urolithin derivatives) that complements existing guideline-directed therapies. By adding this new mechanism of action to standard treatment protocols, the composition addresses the underlying mitochondrial dysfunction that conventional therapies cannot correct. This parameter change enables the treatment to maintain ease of operation (as it can be added to existing protocols) while significantly improving clinical outcomes and reducing morbidity and mortality.
3Adaptability or versatility
If mitochondrial dysfunction is targeted in early stage HCM, then novel therapeutic approaches are proposed, but no therapies are currently available to prevent or treat mitochondrial dysfunction
Solution Approach 1:
The patent employs urolithin derivatives as intermediary compounds that mediate between the need for mitochondrial protection and the availability of safe, effective therapies. These derivatives act as intermediaries by stimulating endogenous mitochondrial biogenesis through the PGC-1α pathway, providing a bridge between conventional therapy and direct mitochondrial intervention. This intermediary approach enables early-stage mitochondrial targeting in HCM while maintaining ease of manufacture and clinical safety, as the compounds can be produced through established pharmaceutical processes.
Data Source
AI summary
The present invention belongs to the field of medicine, and more precisely to the field of medicine useful in the treatment of cardiac diseases with contributing mitochondrial dysfunction.The present invention relates to a composition a pharmaceutical composition comprising a PPAR-modulator and an urolithin derivative of formula I:wherein R1, R2 and R3 independently represents H or OH and its use thereof in the treatment of various cardiac diseases linked to cardiac diseases with contributing mitochondrial dysfunction.